An official website of the United States government

NIH: National Institute of Diabetes and Digestive and Kidney Diseases
NIDDK Central Repository
Search
Filters

Study Acronym

Virahep-C

1 - 28 of 28 Results
  • 1
Page
Show:
Study Search Results Table
Title
PMID
PMCID
Public Release Type
Publication Year
DOI
Study Acronym
Request ID(s)
Public Release Origin
A novel unsupervised method to identify genes important in the anti-viral response: application to interferon/ribavirin in hepatitis C patients.17589564PMC1978073Journal200710.1371/journal.pone.0000584Virahep-CContributing Study
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.23291588PMC3793390Journal201310.1038/ng.2521Virahep-C428, 10180, 10320, 10400, 10618Secondary Research
Assessing the validity of self-reported medication adherence in hepatitis C treatment.17519299Journal200710.1345/aph.1K024Virahep-CContributing Study
Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C.18571276PMC2609954Journal200810.1016/j.jhep.2008.04.011Virahep-CContributing Study
Associations between serum lipids and hepatitis C antiviral treatment efficacy.20690192PMC2938827Journal201010.1002/hep.23796Virahep-CContributing Study
Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection.18418397PMC2696808Journal200810.1038/gene.2008.21Virahep-CContributing Study
Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy.17267482PMC1866036Journal200710.1128/JVI.02640-06Virahep-CContributing Study
Comparison of approaches for incorporating new information into existing risk prediction models.27943382Journal201710.1002/sim.7190HALT-C, Virahep-C10835Secondary Research
Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.26186989PMC4615534Journal201510.1016/j.jhep.2015.06.035Virahep-C, HALT-C10835Secondary Research
Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients.20140258PMC2815788Journal201010.1371/journal.pone.0009032Virahep-CContributing Study
Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans.19104147PMC2613460Journal200910.1172/JCI37085Virahep-CContributing Study
Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy.18463735PMC2373758Journal200810.1371/journal.pone.0002123Virahep-CContributing Study
High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity.26344576PMC4744814Journal201610.1111/liv.12932Virahep-C10433Secondary Research
Host genetics, steatosis and insulin resistance among African Americans and Caucasian Americans with hepatitis C virus genotype-1 infection.19401628PMC2803674Journal200910.1159/000214380Virahep-CContributing Study
Immune evasion versus recovery after acute hepatitis C virus infection from a shared source.15939788PMC2213272Journal200510.1084/jem.20042284Virahep-CContributing Study
Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes.19193669PMC2689392Journal200910.1136/gut.2008.168948Virahep-CContributing Study
Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection.19387461PMC2810514Journal200910.1038/gene.2009.26Virahep-CContributing Study
Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection.17006909Journal200610.1002/hep.21335Virahep-CContributing Study
Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus.17526009Journal200710.1002/hep.21636Virahep-CContributing Study
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.16890601Journal200610.1053/j.gastro.2006.06.008Virahep-CContributing Study
Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection.18407798PMC2704736Journal200810.1016/j.cgh.2008.02.035Virahep-CContributing Study
Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients.26314558PMC4592471Journal201510.1111/apt.13389Virahep-C10433Secondary Research
Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C.18852273PMC2630649Journal200910.1128/AAC.00947-08Virahep-CContributing Study
Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy.17522222PMC1951276Journal200710.1128/JVI.00487-07Virahep-CContributing Study
Race, insulin resistance and hepatic steatosis in chronic hepatitis C.17187406Journal200710.1002/hep.21455Virahep-CContributing Study
Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy.17659573Journal200710.1002/hep.21714Virahep-CContributing Study
Serum lipids and their associations with viral levels and liver disease severity in a treatment-naïve chronic hepatitis C type 1-infected cohort.21070504Journal201110.1111/j.1365-2893.2010.01394.xVirahep-CContributing Study
Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.19434718PMC2692559Journal200910.1002/hep.22877Virahep-CContributing Study
  • 1
Page